Abstract
BackgroundLiver cancer is one of the most malignant human cancers, with few treatments and a poor prognosis. Erianin (ERN) is a natural compound with multiple pharmacological activities that has been reported to have numerous excellent effects against liver cancer in experimental systems. However, its application in vivo has been limited due to its poor aqueous solubility and numerous off-target effects. This study aimed to improve the therapeutic efficacy of ERN by developing novel ERN-loaded tumor-targeting nanoparticles.ResultsIn this study, ERN was loaded into liposomes by ethanol injection (LP-ERN), and the resulting LP-ERN nanoparticles were treated with transferrin to form Tf-LP-ERN to improve the solubility and enhance the tumor-targeting of ERN. LP-ERN and Tf-LP-ERN nanoparticles had smooth surfaces and a uniform particle size, with particle diameters of 62.60 nm and 88.63 nm, respectively. In HepG2 and SMMC-7721 cells, Tf-LP-ERN induced apoptosis, decreased mitochondrial membrane potentials and increased ERN uptake more effectively than free ERN and LP-ERN. In xenotransplanted mice, Tf-LP-ERN inhibited tumor growth, but had a minimal effect on body weight and organ morphology. In addition, Tf-LP-ERN nanoparticles targeted tumors more effectively than free ERN and LP-ERN nanoparticles, and in tumor tissues Tf-LP-ERN nanoparticles promoted the cleavage PARP-1, caspase-3 and caspase-9, increased the expression levels of Bax, Bad, PUMA, and reduced the expression level of Bcl-2. Moreover, in the spleen of heterotopic tumor model BALB/c mice, ERN, LP-ERN and Tf-LP-ERN nanoparticles increased the expression levels of Nrf2, HO-1, SOD-1 and SOD-2, but reduced the expression levels of P-IKKα+β and P-NF-κB, with Tf-LP-ERN nanoparticles being most effective in this regard. Tf-LP-ERN nanoparticles also regulated the expression levels of TNF-α, IL-10 and CCL11 in serum.ConclusionTf-LP-ERN nanoparticles exhibited excellent anti-liver cancer activity in vivo and in vitro by inducing cellular apoptosis, exhibiting immunoregulatory actions, and targeting tumor tissues, and did so more effectively than free ERN and LP-ERN nanoparticles. These results suggest that the clinical utility of a Tf-conjugated LP ERN-delivery system for the treatment of liver cancer warrants exploration.
Highlights
Liver cancer is the world’s third most common cause of cancerrelated deaths, due to its frequent recurrence and formation of metastases, and a lack of effective treatments [1, 2]
There was no significant change in the polydispersity index (PDI) of the nanoparticles, indicating that the LPs prepared by ethanol injection had good reproducibility and a uniform particle-size distribution
Our previous study found that ERN exerts anti-liver cancer effects by regulating mitochondrial apoptosis and the immune response [17]; its biopharmaceutical applications have been hampered due to its poor aqueous solubility and tumortargeting ability
Summary
Liver cancer is the world’s third most common cause of cancerrelated deaths, due to its frequent recurrence and formation of metastases, and a lack of effective treatments [1, 2]. It is most prevalent in Asia and Africa; its incidence is increasing in Western countries [3]. Caspase-3 is a crucial proapoptotic protein in caspase cascades, and is considered to be a key factor of mitochondrial apoptosis [7]. This study aimed to improve the therapeutic efficacy of ERN by developing novel ERN-loaded tumortargeting nanoparticles
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have